CoChat

Antidepressants in Inflammatory Bowel Disease: A Systematic Review

Open access
Macer, Benjamin J. D., Prady, Stephanie L., Mikocka-Walus, Antonina · 2017 · Inflammatory Bowel Diseases

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 7 of the 113 sources its claims cite were checked for support.

Abstract

BACKGROUND: Antidepressants are commonly used to treat symptoms of anxiety and depression in inflammatory bowel disease (IBD). Recent studies suggest a link between IBD activity and an individual's emotional state which raises the possibility that antidepressants may potentially modify the disease course of IBD. This systematic review thus primarily aims to evaluate the efficacy of antidepressants on IBD activity, and secondarily, on anxiety and depression. METHODS: MEDLINE, EMBASE, Cochrane (IBD Group), CINAHL, AMED, PsycINFO, and OpenGrey were searched from 1990 onward with no restrictions on study design. A quality appraisal was conducted using several scales as appropriate for each study design. A narrative synthesis was also conducted. RESULTS: Fifteen eligible studies included in the review (1 randomized controlled trial, 2 cohorts, 1 case-control, 1 cross-sectional survey, 1 qualitative, 2 audits, 1 case series, and 6 case reports) examined a range of antidepressants. Twelve studies suggested that antidepressants have a positive impact on IBD course. Nine studies reported anxiety and depression as an outcome, of these 8 reported beneficial effects of antidepressants. Most of the studies were deemed to be at low risk of bias, apart from the case reports, which were at high risk of bias. CONCLUSIONS: This research indicates that antidepressants may have a beneficial effect on IBD course. However, it is currently not possible to determine their efficacy for certain because of the lack of randomized trials. Further trials using objective measures of IBD activity, longer follow-up periods, and larger sample sizes are needed.

Overview

CoChat Summary

## TL;DR

This systematic review found that antidepressants are commonly used in IBD and that 12 of 15 included studies suggested a positive impact on IBD course, but the authors conclude that efficacy cannot be determined for certain because the evidence is mostly observational. Evidence for anxiety/depression outcomes was also generally favorable, with 8 of 9 studies reporting benefit.

## Key findings

  • The review included 15 studies: 1 placebo-controlled RCT, 2 cohorts, 1 case-control study, 1 cross-sectional survey, 1 qualitative study, 2 audits, 1 case-series, and 6 case reports.
  • 12 studies suggested antidepressants had a positive impact on IBD course; 9 studies reported anxiety/depression as an outcome, and 8 of these reported beneficial effects.
  • In the RCT, 44 participants were randomized to duloxetine 60 mg daily or placebo for 12 weeks; symptom severity improved in the intervention group (P = 0.02), and depression/anxiety also improved (P = 0.041 and P = 0.049).
  • In the retrospective case-control study, the antidepressant group had fewer relapses and steroid courses after starting antidepressants than before (relapses P = 0.002; steroids P < 0.001), and relapses differed significantly vs controls (P = 0.03).
  • In the cross-sectional survey of 98 participants, 79% reported perceived improvements, 67% reported no change in perceived disease activity, 25% reported disease activity improvement, and 87% reported improved psychological well-being.

## Methods

  • Systematic review of antidepressants in human IBD, with no restriction on study design; searches were run in MEDLINE, EMBASE, Cochrane IBD Group, CINAHL, AMED, PsycINFO, and Open Grey from 1990 onwards.
  • Included studies had to involve clinically diagnosed IBD and an antidepressant exposure (tricyclics, MAOIs, SSRIs, SNRIs, or atypical antidepressants), with outcomes on IBD remission/activity or anxiety/depression.
  • The authors conducted quality appraisal using design-appropriate tools and used a narrative synthesis; a meta-analysis was planned but not done because of heterogeneity in study design and outcomes.

## Limitations

  • The paper states that most included studies were observational, uncontrolled, and non-randomised, so “no firm conclusions” can be drawn about efficacy; the review also notes only one RCT and six case reports among the 15 studies.
  • The authors state that many studies had small sample sizes, single-source sampling, and short follow-up; only 3 studies had follow-up of 2 years or more, while 5 had follow-up of 12 weeks or less.
  • Evident from the text: the review included only English-language papers for practical reasons, and one author conducted screening/data extraction; the text explicitly identifies these as limitations of the review.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1097/mib.0000000000001059

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

5 Valid · 2 Not valid · 101 Not checked · 30 Own results and interpretations

50 more claims · 1 with their cited sources checked

Create a free account to see all 138 claims and to verify the 98 references still open.

See all claims — free account
  • Probably not a substantial claim. 58
  • The quote only partly states this claim. 3
  • It may state two separate claims as one. 45

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 29 references

Research works printed but not linked: 4

  1. Mikocka-Walus, 2009, Eur Gastroeneterol and Hepatol Rev, 5, 1
  2. Ramos Rivers, 2014, Gastroenterology, 1, S
  3. Kahn, 2014, J Gen Intern Med, 29, S348
  4. Fuller-Thomson, 2006, Inflamm Bowel Dis, 12, 697, 10.1097/00054725-200608000-00005 · DOI · Paper page

Cited by

See all 106

Metadata

Authors
Macer, B. J. D., Prady, S. L., & Mikocka-Walus, A.
Affiliations
  • Deakin University (AU)
  • University of York (GB)
Venue
Inflammatory Bowel Diseases
Published
2017-04
Volume
23
Issue
4
Pages
534-550
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2592131189
Cited by
92
References
29
Citations by year
2026: 2 · 2025: 8 · 2024: 12 · 2023: 8 · 2022: 15 · 2021: 17 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 5
FWCI
1.05
Type
journal article
Language
en
Open access
Locations
  • Inflammatory Bowel Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
  • Figshare (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
antidepressants, inflammatory bowel disease
MeSH terms
Antidepressive Agents, Anxiety, Depression, Humans, Inflammatory Bowel Diseases, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressants in Inflammatory Bowel Disease: A Systematic Review. https://app.cochat.ai/papers/10.1097/mib.0000000000001059
The paper
Macer, B. J. D., Prady, S. L., & Mikocka-Walus, A. (2017). Antidepressants in Inflammatory Bowel Disease: A Systematic Review. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000001059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.